Company: SUPN
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0001104659-25-042531
Chunk: 26

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 26
---
5% of any class of our voting securities or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest. We believe the arrangement set forth below is on terms no less favorable to us than we could have obtained from unaffiliated third parties. The arrangement described below was approved by the Audit Committee under the Audit Committee charter. We employ an adult daughter of Mr. Khattar in a non-executive, managerial capacity as an Associate Director, Marketing. This individual, who does not reside with and is not supported financially by Mr. Khattar, earned total compensation for fiscal year 2024 of $182,616 and total compensation for fiscal year 2023 of $177,747, which is commensurate with her peers and exclusive of unvested options awarded to her. Mr. Khattar’s daughter is employed on an “at will” basis and compensated on the same basis as our other employees of similar function, seniority and responsibility without regard to her relationship with Mr. Khattar. In addition, the criteria used to complete the hiring decision regarding Mr. Khattar’s daughter were the same criteria used to hire other Associate Directors, Marketing. Meetings During the year ended December 31, 2024, the Board of Directors held a total of six (6) meetings. Each of our directors, except for Ms. Sensenig, attended at least 75% of the aggregate number of meetings of the Board of Directors and meetings of any committee of which he or she was a member, which were held during the time in which he or she was a director or a committee member. During the year ended December 31, 2024, Ms. Sensenig attended 67% and 80% of the meetings of the Board of Directors and the Audit Committee, respectively. Each member of the Board of Directors who is up for election at the Annual Meeting of Stockholders or who has a term that continues after such meeting is expected to attend the Annual Meeting of Stockholders. Messrs. Hudson and Khattar attended the 2024 Annual Meeting of Stockholders, which was held on June 14, 2024. Stockholder Communications with the Board of Directors We have established procedures for stockholders to communicate directly with our Board of Directors on a confidential basis. Stockholders who wish to communicate with the Board of Directors or with a particular director may send a letter to the Secretary of Supernus Pharmaceuticals, Inc. at 9715 Key